Embolization Particle Market Size, Share, and Industry Analysis, By Type (Radioembolization Spheres, Microspheres, Drug Eluting Beads (DEBs), and Others), By Application (Uterine Fibroid Embolization (UFE), Tumor Treatment, Hemorrhage, and Others), By End-user (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

The global embolization particle market is witnessing significant growth driven by factors such as advancements in technology, increasing prevalence of target diseases, and the rising demand for minimally invasive procedures.

• For instance, an article published by ScienceDirect in 2022 stated that the development of tissue adhesive embolization microspheres with imaging ability may hold a significant potential to improve the efficacy of interventional embolization. Such advances in embolization particles may increase their use among healthcare providers, driving market expansion in the coming years.

Embolization Particle Market Driver

Rising Prevalence of Target Diseases to Boost Market Growth

The incidence of conditions such as liver cancer, uterine fibroids, and peripheral vascular diseases is on the rise globally. These diseases often require effective treatments such as embolization, which blocks blood flow to tumors or abnormal tissues, thereby preventing their growth and spread. Moreover, the rising global cancer rates are significantly contributing to the demand for several embolization therapies involving the use of embolization particles. Such a scenario is anticipated to propel the market growth.

• For instance, according to data published by the American Cancer Society, Inc., in January 2024, about 41,630 new liver cancer cases were estimated to be diagnosed in the U.S. that year. Such a scenario is expected to drive the usage of embolization particles, driving market expansion.

Download Free sample to learn more about this report.

According to data published by the American Cancer Society, Inc., 41,630 were projected to occur in the U.S., witnessing significant growth as compared to 2023.

Embolization Particle Market Restraint

Limited Awareness and Acceptance of Embolization Procedures May Hamper the Market Growth

Despite the increasing demand for embolization particles in various medical applications, awareness about embolization procedures is still limited among patients and some healthcare providers in a few regions. Moreover, the hesitation to adopt new treatment methods over traditional approaches can restrict market penetration. Such a scenario is anticipated to hamper the market growth.

• For instance, as per a study published by the Canadian Association of Radiologists Journal in May 2024, it was reported that respondents believe patients in Canada still have limited awareness of uterine fibroid embolization (UFE) across the country. Such limited awareness may hamper the market expansion.

Embolization Particle Market Opportunity

Innovations in Embolization Particle May Spur Market Expansion

Recent innovations in embolization particle materials, such as drug-eluting beads (DEBs) and microspheres, have enhanced the precision and effectiveness of these treatments. DEBs allow for localized drug delivery directly to tumors, improving treatment outcomes while minimizing damage to surrounding healthy tissues. Such advancements are transforming treatment approaches and expanding the range of applications for embolization techniques, which is anticipated to contribute to market growth in the near future.

• For instance, according to an article published by the NCBI in August 2021, it was mentioned that drug-eluting bead TACE (DEB-TACE) demonstrated several advantages in terms of survival, treatment response, and adverse effects compared to the conventional TACE (c-TACE). This may increase the product demand globally, propelling the market growth.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Conditions, By Key Countries/Region, 2023
• New Product Launches, By Key Players
• Overview: Advancements in Embolization Particles
• Key Industry Developments (Mergers, Acquisitions, and Partnerships)
• Impact of COVID-19 on the Market

Analysis by Type

Based on type, the market is fragmented into radioembolization spheres, microspheres, drug eluting beads (DEBs), and others.

The microspheres segment is expected to hold a major share of the global market. The segment growth can be attributed to the ability of microspheres to enhance treatment outcomes in various medical procedures, making them a preferred choice among clinicians. Moreover, these types of particles are commonly employed in Tran’s arterial chemoembolization (TACE) for liver tumors. Additionally, the microspheres offer better flow properties and ease of delivery through injection procedures.

• For instance, according to an article published by ACS Publications in January 2024, microspheres have been widely used and explored for localized cancer treatment, which is driving its demand and is expected to contribute to market growth.

Analysis by Application

Based on application, the market is divided into uterine fibroid embolization (UFE), tumor treatment, hemorrhage, and others.

The tumor treatment segment is expected to hold a substantial share of the global market. The segment's growth can be attributed to the high burden of liver tumors, which is propelling the demand for embolization particles. Moreover, this is expected to increase the focus of key players on launching embolization particles for tumor treatment, contributing to the segment growth.

• For instance, according to an article published by the Journal of Hepatology in December 2022, 905,700 people were diagnosed with liver cancer globally in 2020, and this number is projected to rise to more than 55.0% by 2040. This is expected to boost the segment growth over the coming years.

Analysis by End-user

By end-user, the market is subdivided into hospitals, specialty clinics, and others.

The hospitals segment is projected to account for a major market share during the projection period. The growth is mainly attributed to the increasing number of hospitals worldwide, which may support the embolization procedures involving the use of embolization particles, propelling the segment growth.

• For instance, according to data published by Above & Beyond ABA Therapy in April 2024, there were 7,335 active hospitals in the U.S. as of January 2023. This high number of hospitals may contribute to the rising number of embolization procedures, which is expected to boost the segment growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global embolization particle market in 2023. The regional growth is attributed to the increasing cases of hemorrhage across the region's key countries, which is projected to drive the demand for embolization particles.

• For instance, according to an article published by the NCBI in January 2023, the rate of postpartum hemorrhage (PPH) in the U.S. increased from 2.7% to 4.3% between 2000 and 2019. Embolization is considered a safe and effective treatment for hemorrhage, which is likely to propel the region's market growth.

Europe is the second-largest market based on the demand for embolization particle products. The growth is attributed to the well-established healthcare infrastructure in the key countries of the region. Moreover, the presence of prominent players in the region, contributing to high penetration of embolization particles, is also expected to boost the regional market growth.

The Asia Pacific is expected to grow at the highest CAGR during the forecast period. The regional growth can be attributed to the rising number of traumas and OPD cases in the region, which may surge the demand for embolization particles to control the bleeding. This is anticipated to boost the regional market expansion over the forthcoming years.

• For instance, in October 2024, the Times of India reported that there was a four-fold increase in outpatient department cases (OPD), rising from 4,274 in 2019 to 3,894 in 2023. Such a growth in trauma cases may spur the demand for embolization particles, thereby driving the regional market growth.

Key Players Covered

The global embolization particle market is fragmented, with many companies offering various products.

The report includes the profiles of the following key players:

• Boston Scientific Corporation (U.S.)
• Merit Medical Systems (U.S.)
• Sirtex SIR-Spheres Pty Ltd. (Australia)
• TERUMO CORPORATION (Japan)
• Cook (U.S.)
• Varian Medical Systems, Inc. (U.S.)
• KAVYA PHARMA (India)
• Guerbet (France)
• Medtronic (U.K.)

Key Industry Developments

• In September 2024, Sirtex SIR-Spheres Pty Ltd., obtained certification according to Medical Device Regulation (EU) 2017/745 for SIR-Spheres Y-90 resin microspheres and its delivery systems for liver cancer treatment.
• In August 2024, Sirtex SIR-Spheres Pty Ltd., launched the SIR-Spheres FLEXdose SELECT delivery program to offer precise Y-90 selective internal radiation therapy for the treatment of metastatic colorectal cancer.